Costa O, Monier J C
J Rheumatol. 1986 Aug;13(4):722-5.
Antihistone antibodies were sought in sera from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), melanomas, leukemias and other cancers (particularly breast cancer) by micro-ELISA, using a solution of total histones as antigen. This solution contained H1 and core histones (H2A, H2B, H3 and H4). ELISA was positive in 59.8% of SLE cases, 5.2% of RA cases, 11.1% of melanomas, 13.6% of leukemias and 5.6% of other cancers. Immunoblotting using total histones enabled us to clarify the histone fraction recognized by antihistone antibodies. In SLE, these were mainly anti-H1 and anti-H2B antibodies. In RA, antibodies recognized all histone fractions. However, some sera from patients with RA stained the H4 band more intensely.
采用微量酶联免疫吸附测定法（micro-ELISA），以总组蛋白溶液作为抗原，检测系统性红斑狼疮（SLE）、类风湿关节炎（RA）、黑色素瘤、白血病及其他癌症（尤其是乳腺癌）患者血清中的抗组蛋白抗体。该溶液包含H1和核心组蛋白（H2A、H2B、H3和H4）。酶联免疫吸附测定法结果显示，SLE患者阳性率为59.8%，RA患者为5.2%，黑色素瘤患者为11.1%，白血病患者为13.6%，其他癌症患者为5.6%。使用总组蛋白进行免疫印迹分析，使我们能够明确抗组蛋白抗体识别的组蛋白组分。在SLE中，主要是抗H1和抗H2B抗体。在RA中，抗体可识别所有组蛋白组分。然而，一些RA患者的血清对H4条带的染色更为强烈。
